Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.
An observational study of 35,064 adults born with heart defects and diagnosed with artery disease found more complications despite fewer conventional risk factors.An observational study of 35,064 adults born with heart defects and diagnosed with artery disease found more complications despite fewer conventional risk factors.
An observational study of 657 patients found that combining the two measures improved risk prediction beyond standard clinical factors.An observational study of 657 patients found that combining the two measures improved risk prediction beyond standard clinical factors.